Natera Inc (NASDAQ: NTRA)Cassava Sciences Inc
First, we have the clinical-stage biopharmaceutical company, Cassava. The company focuses on developing drugs for the treatment of nervous system disorders. Cassava is currently in focus due to the spotlight on the treatment of Alzheimerâs disease. This comes after Biogen Inc (NASDAQ: BIIB) received an accelerated FDA approval for its drug ADUHELMâ¢. So, investors appear to be optimistic that Cassavaâs simufilam and SavaDx may benefit from this development. Â
Simufilam is Cassavaâs lead drug candidate to treat Alzheimerâs disease while SavaDx is an investigational diagnostic candidate to detect Alzheimerâs. The company will be presenting its results of an interim analysis on safety and cognition for the first 50 subjects to complete 9 months of open-label drug treatment. These data will be presented at the 2021 Alzheimerâs Association International Conference (AAIC) in Denver scheduled for 26th to